Compare
Starling Oncology, Inc. vs LifeMD, Inc. vs SBC Medical Group Holdings Inc vs Airsculpt Technologies, Inc.
| Latest fiscal year | Starling Oncology, Inc. STLN | LifeMD, Inc. LFMD | SBC Medical Group Holdings Inc SBC | Airsculpt Technologies, Inc. AIRS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $502.73M | $194.06M | $173.61M | $151.82M |
| Revenue growth (YoY) | +27.8% | +25.3% | -15.5% | -15.8% |
| Gross margin | n/a | 85.7% | 73.3% | n/a |
| Operating margin | -7.2% | -4.0% | 38.9% | -7.6% |
| Net margin | -12.1% | 7.4% | 29.4% | -7.7% |
| Net income | -$60.61M | $14.35M | $50.99M | -$11.67M |
| EPS (Diluted) | -$0.54 | $0.25 | $0.50 | -$0.19 |
| Operating cash flow | -$24.59M | $8.28M | $24.67M | $3.10M |
| Free cash flow | -$27.79M | $6.41M | $23.27M | $692.0K |
| Cash & equivalents | n/a | n/a | $163.77M | $8.45M |
| Total assets | $164.66M | $70.41M | $380.45M | $187.30M |
| Total liabilities | $180.38M | $47.25M | $117.14M | $99.59M |
| Shareholders' equity | -$15.72M | $23.16M | $248.28M | $87.71M |
| Return on year-end equity | n/a | 62.0% | 20.5% | -13.3% |
| Shares outstanding | 98.86M | 46.66M | 102.58M | 64.46M |
Revenue, most recent five fiscal years
| Fiscal year | Starling Oncology, Inc. | LifeMD, Inc. | SBC Medical Group Holdings Inc | Airsculpt Technologies, Inc. |
|---|---|---|---|---|
| Latest | $502.73M Ended 2025-12-31 | $194.06M Ended 2025-12-31 | $173.61M Ended 2025-12-31 | $151.82M Ended 2025-12-31 |
| 1 year earlier | $393.41M Ended 2024-12-31 | $154.82M Ended 2024-12-31 | $205.42M Ended 2024-12-31 | $180.35M Ended 2024-12-31 |
| 2 years earlier | $324.24M Ended 2023-12-31 | $152.55M Ended 2023-12-31 | $193.54M Ended 2023-12-31 | $195.92M Ended 2023-12-31 |
| 3 years earlier | $252.48M Ended 2022-12-31 | $119.03M Ended 2022-12-31 | n/a | $168.79M Ended 2022-12-31 |
| 4 years earlier | $203.00M Ended 2021-12-31 | $92.88M Ended 2021-12-31 | n/a | $133.31M Ended 2021-12-31 |